Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg Ball

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Contemporary Clinical Trials|June 10, 2011
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 4: One methodGreg Ball
Pharmaceutical Statistics|May 23, 2019
The importance of cross-disciplinary scientific engagement in the development of quantitative procedures for aggregate safety assessmentsGreg Ball, Fabio Lievano
Contemporary Clinical Trials|June 14, 2011
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 3: Design considerationsGreg Ball, Michael H Silverman
Therapeutic Innovation & Regulatory Science|September 21, 2018
A Bayesian Exposure-Time Method for Clinical Trial Safety Monitoring With Blinded DataPatrick M Schnell, Greg Ball
Contemporary Clinical Trials|June 14, 2011
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 2: Statistical considerationsGreg Ball, Linda B Piller
Pharmaceutical Statistics|January 3, 2023
Just say no to data listings!Mercidita Navarro, Nancy Brucken, Aiming Yang, et al.
Contemporary Clinical Trials|June 14, 2011
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 1: Ethical considerationsGreg Ball, Linda B Piller, Michael H Silverman
Therapeutic Innovation & Regulatory Science|March 30, 2024
How Aggregate Safety Assessment Planning Supports Investigational New Drug Safety Reporting DecisionsBarbara A Hendrickson, Cynthia McShea, Greg Ball, et al.
Therapeutic Innovation & Regulatory Science|June 25, 2020
Bayesian Meta-analysis of Safety Outcomes Using Blinded Clinical Trial DataEmily Goren, Li-An Lin, Robert O Blaustein, et al.
Contemporary Clinical Trials|July 1, 2020
Meta-analysis of blinded and unblinded studies for ongoing aggregate safety monitoring and evaluationLi-An Lin, Shuai Sammy Yuan, Lie Li, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Contemporary Clinical Trials|June 10, 2011
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 4: One methodGreg Ball
Pharmaceutical Statistics|May 23, 2019
The importance of cross-disciplinary scientific engagement in the development of quantitative procedures for aggregate safety assessmentsGreg Ball, Fabio Lievano
Contemporary Clinical Trials|June 14, 2011
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 3: Design considerationsGreg Ball, Michael H Silverman
Therapeutic Innovation & Regulatory Science|September 21, 2018
A Bayesian Exposure-Time Method for Clinical Trial Safety Monitoring With Blinded DataPatrick M Schnell, Greg Ball
Contemporary Clinical Trials|June 14, 2011
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 2: Statistical considerationsGreg Ball, Linda B Piller
Pharmaceutical Statistics|January 3, 2023
Just say no to data listings!Mercidita Navarro, Nancy Brucken, Aiming Yang, et al.
Contemporary Clinical Trials|June 14, 2011
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 1: Ethical considerationsGreg Ball, Linda B Piller, Michael H Silverman
Therapeutic Innovation & Regulatory Science|March 30, 2024
How Aggregate Safety Assessment Planning Supports Investigational New Drug Safety Reporting DecisionsBarbara A Hendrickson, Cynthia McShea, Greg Ball, et al.
Therapeutic Innovation & Regulatory Science|June 25, 2020
Bayesian Meta-analysis of Safety Outcomes Using Blinded Clinical Trial DataEmily Goren, Li-An Lin, Robert O Blaustein, et al.
Contemporary Clinical Trials|July 1, 2020
Meta-analysis of blinded and unblinded studies for ongoing aggregate safety monitoring and evaluationLi-An Lin, Shuai Sammy Yuan, Lie Li, et al.
Pageof 3